Bone Marrow Metastases from Solid Organ Cancer in Adults

Author(s):  
Lima Arya ◽  
Deepak Sundriyal ◽  
Rekha Bhandari ◽  
Ruchi Srivastava ◽  
Amit Sehrawat
Blood ◽  
1979 ◽  
Vol 53 (4) ◽  
pp. 677-686 ◽  
Author(s):  
DC Ihde ◽  
EB Simms ◽  
MJ Matthews ◽  
MH Cohen ◽  
PA Bunn ◽  
...  

Author(s):  
Joanna Cwykiel ◽  
Arkadiusz Jundzill ◽  
Aleksandra Klimczak ◽  
Maria Madajka-Niemeyer ◽  
Maria Siemionow

AbstractThis study evaluated the efficacy of donor recipient chimeric cell (DRCC) therapy created by fusion of donor and recipient derived bone marrow cells (BMC) in chimerism and tolerance induction in a rat vascularized composite allograft (VCA) model. Twenty-four VCA (groin flaps) from MHC-mismatched ACI (RT1a) donors were transplanted to Lewis (RT1l) recipients. Rats were randomly divided into (n = 6/group): Group 1—untreated controls, Groups 2—7-day immunosuppression controls, Group 3—DRCC, and Group 4—DRCC with 7-day anti-αβTCR monoclonal antibody and cyclosporine A protocol. DRCC created by polyethylene glycol-mediated fusion of ACI and Lewis BMC were cultured and transplanted (2–4 × 106) to VCA recipients via intraosseous delivery route. Flow cytometry assessed peripheral blood chimerism while fluorescent microscopy and PCR tested the presence of DRCC in the recipient’s blood, bone marrow (BM), and lymphoid organs at the study endpoint (VCA rejection). No complications were observed after DRCC intraosseous delivery. Group 4 presented the longest average VCA survival (79.3 ± 30.9 days) followed by Group 2 (53.3 ± 13.6 days), Group 3 (18 ± 7.5 days), and Group 1 (8.5 ± 1 days). The highest chimerism level was detected in Group 4 (57.9 ± 6.2%) at day 7 post-transplant. The chimerism declined at day 21 post-transplant and remained at 10% level during the entire follow-up period. Single dose of DRCC therapy induced long-term multilineage chimerism and extended VCA survival. DRCC introduces a novel concept of customized donor-recipient cell-based therapy supporting solid organ and VCA transplants.


1995 ◽  
Vol 59 (4) ◽  
pp. 616-620 ◽  
Author(s):  
Adriana Zeevi ◽  
Mary Pavlick ◽  
Susan Lombardozzi ◽  
Richard Banas ◽  
Orit Pappo ◽  
...  

Medicina ◽  
2018 ◽  
Vol 54 (2) ◽  
pp. 27 ◽  
Author(s):  
Wojciech Wołyniec ◽  
Małgorzata Sulima ◽  
Marcin Renke ◽  
Alicja Dębska-Ślizień

Introduction. The immunosuppression used after transplantation (Tx) is associated with an increased risk of opportunistic infections. In Europe, parasitic infections after Tx are much less common than viral, bacterial and fungal ones. However, diseases caused by parasites are very common in tropical countries. In the last years the number of travellers with immunosuppression visiting tropical countries has increased. Methods. We performed a literature review to evaluate a risk of parasitic infections after Tx in Europe. Results. There is a real risk of parasitic infection in patients after Tx travelling to tropical countries. Malaria, leishmaniasis, strongyloidiasis and schistosomiasis are the most dangerous and relatively common. Although the incidence of these tropical infections after Tx has not increased, the course of disease could be fatal. There are also some cosmopolitan parasitic infections dangerous for patients after Tx. The greatest threat in Europe is toxoplasmosis, especially in heart and bone marrow recipients. The most severe manifestations of toxoplasmosis are myocarditis, encephalitis and disseminated disease. Diarrhoea is one of the most common symptoms of parasitic infection. In Europe the most prevalent pathogens causing diarrhoea are Giardia duodenalis and Cryptosporidium. Conclusions. Solid organ and bone marrow transplantations, blood transfusions and immunosuppressive treatment are associated with a small but real risk of parasitic infections in European citizens. In patients with severe parasitic infection, i.e., those with lung or brain involvement or a disseminated disease, the progression is very rapid and the prognosis is bad. Establishing a diagnosis before the patient’s death is challenging.


2016 ◽  
Vol 38 (9) ◽  
pp. 687-689 ◽  
Author(s):  
Suthee Rapisuwon ◽  
Klaus J. Busam ◽  
Kellie Parks ◽  
Paul B. Chapman ◽  
Elsie Lee ◽  
...  

1995 ◽  
Vol 59 (4) ◽  
pp. 616-620 ◽  
Author(s):  
Adriana Zeevi ◽  
Mary Pavlick ◽  
Susan Lombardozzi ◽  
Richard Banas ◽  
Orit Pappo ◽  
...  

Urology ◽  
2005 ◽  
Vol 65 (1) ◽  
pp. 174 ◽  
Author(s):  
Ken-Hong Lim ◽  
Ming-Jer Huang ◽  
Stone Yang ◽  
Ruey-Kuen Hsieh ◽  
Johnson Lin

Sign in / Sign up

Export Citation Format

Share Document